SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001437749-18-015601
Filing Date
2018-08-14
Accepted
2018-08-14 16:16:36
Documents
7
Period of Report
2018-08-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K dffn20180814_8k.htm 8-K 26655
2 EXHIBIT 3.1 ex_121774.htm EX-3.1 2120
3 EXHIBIT 99.1 ex_121775.htm EX-99.1 132127
4 a4.jpg GRAPHIC 13976
5 a3.jpg GRAPHIC 37005
6 a2.jpg GRAPHIC 317100
7 a1.jpg GRAPHIC 100928
  Complete submission text file 0001437749-18-015601.txt   802967
Mailing Address 2020 AVON COURT SUITE 4 CHARLOTTESVILLE VA 22902
Business Address 2020 AVON COURT SUITE 4 CHARLOTTESVILLE VA 22902 (434) 220-0718
Diffusion Pharmaceuticals Inc. (Filer) CIK: 0001053691 (see all company filings)

IRS No.: 300645032 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37942 | Film No.: 181017734
SIC: 2834 Pharmaceutical Preparations